| Code | CSB-RA865173MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Bexmarilimab, targeting STAB1 (Stabilin-1), a multifunctional scavenger receptor expressed primarily on alternatively activated macrophages and sinusoidal endothelial cells. STAB1 plays critical roles in homeostatic processes including clearance of modified self-components, cell adhesion, and regulation of inflammatory responses. This receptor has emerged as an important marker of immunosuppressive tumor-associated macrophages (TAMs) in the tumor microenvironment, where its expression correlates with poor prognosis in various malignancies including colorectal cancer, hepatocellular carcinoma, and other solid tumors.
Bexmarilimab, the reference antibody, is a first-in-class therapeutic monoclonal antibody designed to deplete STAB1-positive immunosuppressive macrophages, thereby enhancing anti-tumor immunity. This biosimilar antibody provides researchers with a valuable tool for investigating STAB1 biology, studying macrophage polarization and function, exploring mechanisms of tumor immune evasion, and developing novel immunotherapeutic strategies. It enables detailed examination of STAB1's role in cancer progression, metastasis, and therapeutic resistance across diverse experimental models.
There are currently no reviews for this product.